The role of adenosine receptors in rheumatoid arthritis

Autoimmunity Reviews

Volumn 10, Issue 2, 2010, Pages 61-64

  Varani, Katia ^a   Padovan, Melissa ^b   Govoni, Marcello ^b   Vincenzi, Fabrizio ^a   Trotta, Francesco ^b   Borea, Pier Andrea ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Adenosine; Adenosine receptors; Inflammation; Rheumatoid arthritis

Indexed keywords

6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE RECEPTOR; ANTIRHEUMATIC AGENT; CF 502; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHOTREXATE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PURINE NUCLEOSIDE; RECEPTOR SUBTYPE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CYTOKINE RELEASE; DISEASE COURSE; DOSE RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; HUMAN; INFLAMMATION; MUSCULOSKELETAL DISEASE; PATHOPHYSIOLOGY; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADENOSINE; ANIMALS; ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATION; PURINERGIC AGONISTS; RECEPTORS, PURINERGIC P1;

EID: 78650417131     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.07.019     Document Type: Review

References (40)

1. Weissmann G. The pathogenesis of rheumatoid arthritis. Bull NYU Hosp Joint Dis 2006, 64:12-15.
2. Lee D.M., Weinblatt M.E. Rheumatoid arthritis. Lancet 2001, 358:903-911.
3. Joseph A., Brasington R., Kahl L., Ranganathan P., Cheng T.P., Atkinson J. Immunologic rheumatic disorders. J Allergy Clin Immunol 2010, 125:204-215.
4. Goldring M.B. Updates on high throughput molecular profiling for the study of rheumatoid arthritis. J Cell Physiol 2007, 213:626-634.
5. Senolt L., Vencovskỳ J., Pavelka K., Ospelt C., Gay S. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 2009, 9:102-107.
6. Caporali R., Pallavicini F.B., Filippini M., Gorla R., Marchesoni A., Favalli E.G., et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 2009, 8:274-280.
7. Furst D.E., Keystone E.C., Fleischmann R., Mease P., Breedveld F.C., Smolen J.S., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2010, 69S1:i2-i29.
8. Saad A.A., Ashcroft D.M., Watson K.D., Symmons D.P., Noyce P.R., Hyrich K.L. British Society for Rheumatology Biologics Register. Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthritis Care Res (Hoboken). 2010, 62(3):345-353.
9. Aletaha D., Funovits J., Smolen J.S. The importance of reporting disease activity states in rheumatoid arthritis clinical trials. Arthritis Rheum 2008, 58:2622-2631.
10. Fredholm B.B. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007, 14:1315-1323.
11. Burnstock G. Purine and pyrimidine receptors. CMLS 2007, 64:1471-1483.
12. 3 adenosine receptors in human lymphocytes: upregulation in T cell activation. Mol Pharm 2004, 65:711-719.
13. 2A adenosine receptors in chronic heart failure and cardiac transplantation. FASEB J 2003, 17:280-282.
14. 2B receptors. Biochem Pharm 2005, 70:1601-1612.
15. 3 adenosine receptor: pharmacology and role in disease. Handb Exp Pharmacol 2009, 193:297-327. C.N. Wilson, J.M. Mustafa (Eds.).
16. Varani K., Caramori G., Vincenzi F., Adcock I., Casolari P., Leung E., et al. Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:398-406.
17. 2A adenosine receptor overexpression and functionality, as well as TNF-α, correlate with motor symptoms in Parkinson's disease. FASEB J 2010, 24(2):587-598.
18. 2A receptor function in peripheral blood cells of Huntington's disease patients and at risk mutation carriers. FASEB J 2003, 17:2148-2150.
19. 2A receptors in a large representation of polyglutamine disorders and Huntington's disease stages. Neurobiol Dis 2007, 27:36-43.
20. 3 adenosine receptors in human colonrectal cancer is reflected in peripheral blood cells. Clin Cancer Res 2004, 10:5895-5901.
21. Tesch A.M., MacDonald M.H., Kollias-Baker C., Benton H.P. Endogenously produced adenosine regulates articular cartilage matrix homeostasis: enzymatic depletion of adenosine stimulates matrix degradation. OAC 2004, 12:349-359.
22. 2A receptor agonist. J Orthop Res 2004, 22:427-435.
23. 2A receptor agonist reduces interleukin-8 expression and glycosaminoglycan loss following septic arthrosis. J Orthop Res 2005, 23:1172-1178.
24. Boyle D.L., Moore J., Yang L., Sorkin L.S., Firestein G.S. Spinal of adenosine receptor activation inhibits inflammation and joint destruction in rat adjiuvant induced arthritis. Arth Rheum 2002, 46:3076-3082.
25. Fishman P., Bar-Yehuda S., Madi L., Rath-Wolfson L., Ochaion A., Cohen S., et al. The PI3K-NF-kB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arth Res Ther 2006, 8:R33.
26. Nakamachi Y., Koshiba M., Nakazawa T., Hatachi S., Saura R., Kurosaka M., et al. Specific increase in enzymatic activity of adenosine deaminase 1 in rheumatoid synovial fibroblasts. Arth Rheum 2003, 48:668-674.
27. Morovic-Vergles J., Culo M.I., Gamulin S., Culo F. Cyclic adenosine 5'-monophosphate in synovial fluid of rheumatoid arthritis and osteoarthritis patients. Rheum Int 2008, 29:167-171.
28. Forrest C.M., Harman G., McMillan R.B., Stoy N., Stone T.W., Darlington L.G. Modulation of cytokine release by purine receptors in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005, 23:89-92.
29. 3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin Investig Drugs 2007, 16:1601-1613.
30. 3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J Rheumatol 2008, 35:41-48.
31. 3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor α but not methotrexate. Arth Rheum 2009, 60:2880-2891.
32. Varani K., Vincenzi F., Tosi A., Targa M., Masieri F.F., Ongaro A. Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes. Br J Pharmacol 2010, 160:101-115.
33. Bar-Yehuda S., Rath-Wolfson L., Del Valle L., Ochaion A., Cohen S., Patoka R., et al. Induction of an anti-inflammatory effect and prevention of cartilage damage in rat knee ostheoarthritis by CF101 teratment. Arthritis Rheum 2009, 60:3061-3071.
34. 3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. Cell Immunol 2009, 258:115-122.
35. 3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis. Clin Exp Rheumatol 2006, 24:400-406.
36. 3 adenosine receptor agonist, in healthy young men. Int J Clin Pharmacol Ther 2004, 42:534-542.
37. Silverman M.H., Strand V., Markovits D., Nahir M., Reiblat T., Molad Y., et al. Clinical evidence for utilization of the A3 adenosine receptor as a teraget to treat rheumatoid arthritis: data from a phase II clinical trial. J Rheumatol 2008, 35:41-48.
38. 3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics 2009, 15:291-298. P.A. Borea (Ed.).
39. 3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-κB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant induced arthritis rats. Biochem Pharmacol 2008, 76:482-494.
40. Grabar P., Rojko S., Dusan L., Dolzan V. Genetic determinants of methotrexate treatmnt in rheumatoid arthritis: a study of polymorphisms in the adenosine pathway. Ann Rheum Dis 2010, 69:932.